The Veterinary Resources Support Facility is operated out of the Department of Veterinary Sciences, a component of the M.D. Anderson Science Park. This CCSG-support CORE facility provides a cost-effective, Cancer Center-wide Rodent Serology Program that supports the health of rodent research colonies and the operation of SPF facilities throughout the institution, where utilization approaches 100,000 rodents per year. At the Science Park campus, serology and other forms of health and genetic assessment comprise the Rodent Health and Genetic Quality Assurance Program, integral to maintenance of 14,500 SPF rodents and the numerous inbred and transgenic breeding production colonies maintained at that campus. These programs provide animal health information that is vital to the utilization of defined animal models that are free of intercurrent disease or silent infections. These goals are particularly critical for complex cancer models in areas such as carcinogenesis, chemoprevention, and gene-, immuno-, biological-, and radio-therapy. The Veterinary Resources Support Facility also provides a clinical veterinarian (65%) that oversees the rodent facilities at both Science Park campuses, provides specialized research services, managed breeding production colonies, and assists MDACC investigators with custom polyclonal antisera production (cost recovered). We are requesting new funds to provide investigators with assistance in transgenic breeding management and PCR sample collection as part of the services of producing transgenic animals. An electronic communique for institutional transgenic users and mechanisms for re-deriving imported transgenics harboring pathogens will also be established.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Gadhikar, Mayur A; Zhang, Jiexin; Shen, Li et al. (2018) CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78:781-797
Vial, Macarena R; O'Connell, Oisin J; Grosu, Horiana B et al. (2018) Diagnostic performance of endobronchial ultrasound-guided mediastinal lymph node sampling in early stage non-small cell lung cancer: A prospective study. Respirology 23:76-81
Housten, Ashley J; Lowenstein, Lisa M; Leal, Viola B et al. (2018) Responsiveness of a Brief Measure of Lung Cancer Screening Knowledge. J Cancer Educ 33:842-846
Bose, Prithviraj; Swaminathan, Mahesh (2018) Janus kinase inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34:935-937
Unver, Nese; Delgado, Oliver; Zeleke, Kirubel et al. (2018) Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol. Int J Cancer 142:1405-1417
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Ferguson, Sherise D; Zheng, Siyuan; Xiu, Joanne et al. (2018) Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer 143:3019-3026
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Yazbeck, Victor; Shafer, Danielle; Perkins, Edward B et al. (2018) A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18:569-575.e1

Showing the most recent 10 out of 12418 publications